OrthoPediatrics Corp. Reports First Quarter 2026 Financial Results and Increases 2026 Financial Guidance
OrthoPediatrics Corp. reported a 13% increase in Q1 2026 revenue to $59.4 million driven by growth in Trauma & Deformity, Scoliosis, and OPSB product lines. Adjusted EBITDA improved to $2.2 million from a loss last year and free cash flow usage decreased 40%. The company raised its 2026 revenue guidance to $263-267 million, expecting 11-13% growth.…